

Our ref: IG/FOI/FOI.360.25

16 June 2025

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 10 June 2025, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require. For ease of reference your request is set out below and my response follows.

Your Freedom of Information (FOI) Request:

I have a freedom of information request.

Q1. How many patients have been treated with the following drugs in the past 4 months:

- Atogepant (Aquipta) – any disease
- Erenumab (Aimovig) - any disease
- Eptinezumab (Vyepiti) – any disease
- Fremanezumab (Ajovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vydura) – any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Q2. How many patients have you treated in the last 4 months for acute migraine with:

- Rimegepant (Vydura)

Q3. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Powys Response:

Q1 - Q2. I can confirm that Rimegepant (Vydura) and Atogepant (Aquipta) may be prescribed by primary care in Powys Teaching Health Board (PTHB), however

the health board does not have access to patient-level data; this data is held at GP practice level.

Data regarding the number of items/quantities prescribed in primary care is publicly available via NHS Wales Shared Partnership (NWSSP): [General Practice Prescribing Data Extract - NHS Wales Shared Services Partnership](#)

PTHB does not initiate treatment with any of the other medication listed; patients are treated by providers outside of Powys. PTHB commissions services from a number of Welsh health boards and English provider organisations.

Due to the complex nature of PTHB's commissioning arrangements, not all of our providers indicate the indication for use for each episode of care where these drugs are used. For this reason, PTHB does not hold the data relating to your request, however, the health board is working closely with providers to ensure that this information can be provided in the future. We therefore recommend that you approach our providers for this information directly:

Health Trust/Organisation	FOI Contact Details
Gloucestershire Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Midlands Partnership University NHS Foundation Trust	FOI@mpft.nhs.uk
Sandwell and West Birmingham NHS Trust	swb-tr.SWBH-GM-FOIRequests@nhs.net
The Shrewsbury and Telford Hospital NHS Trust	sath.foi@nhs.net
The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Worcestershire Acute Hospitals NHS Trust	wah-tr.FOI@nhs.net
Wye Valley NHS Trust	Freedom.Information@wvt.nhs.uk

Health Board/Organisation	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk
Cwm Taf Morgannwg University Health Board	Freedomofinformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk

Q3. Not applicable.

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via Powys.FOI@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.